İrem GÖL -TDO- The drug that was believed to be the best prospect for a possible drug for Covid-19 failed to have any effect in the first full trial. The US president Donald Trump had claimed that the medicine was promising. Due to the claims that it may be an effective drug against the coronavirus, the medicine is in short supply globally.
In the trials, which included 237 patients, the ones who took remdesivir did not show any detectable and measurable effects. Also because of the side-effects it generated, the trials stopped early. News of the failure was posted on the database of World Health Organization. Yet it was removed later. A WHO spokesman Tarik Jasarevic said: “A draft document was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed. The manuscript is undergoing peer review and we are waiting for a final version before WHO comments.”
The drug has been manufactured by the US based Gilead Sciences. It is an antiviral that was tested in Ebola, but failed to show benefits in Africa. The trial which was carried out in China, on patients with severe Covid-19 symptoms showed no effect on the treatment. However, Gilead Sciences claims there were still signs that it could be useful, possibly in patients with milder versions of the disease.